Fractionated Stereotactic Radiotherapy in Patients With Acromegaly. Single Centre Experience
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Acromegaly
- Sponsor
- Rigshospitalet, Denmark
- Enrollment
- 34
- Locations
- 1
- Primary Endpoint
- Tumour control by pituitary MRI
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
Hypothesis: Fractionated stereotactic radiotherapy is a safe therapy for treatment of patients with acromegaly in terms of both tumour control and biochemical remission
Detailed Description
An audit was done on 34 patients with acromegaly (consecutive cohorte) treated with fractionated stereotactic radiotherapy in Rigshospitalet/National University Hospital, Copenhagen, Denmark. All patients had MR control regularly to monitor tunour control, and biochemical control assessed by growth hormone measurements during an oral glucose tolerance test. Furthermore all other pituitary axes were tested for sufficiency and concomitant medication likewise registered. The 7 year interim analysis demonstrated an acceptable tumour control and biochemical remission profile, and most patient had subsequent withdrawal of somatostatin analogue- and growth hormone receptor antagonis therapy. The observational study will continue with a new update in approx 2 years
Investigators
Ulla Feldt-Rasmussen
Professor, chief Physician
Rigshospitalet, Denmark
Eligibility Criteria
Inclusion Criteria
- •adults active acromegaly pituitary tumour on MRI biochemical activity -
Exclusion Criteria
- •pregnancy no visible tumour on MRI
Outcomes
Primary Outcomes
Tumour control by pituitary MRI
Time Frame: 7 years
Secondary Outcomes
- biochemical remission(10 years)
- withdrawal of somatostatin analogue and growth hormone receptor antagomist(10 years)
- Affection of other pituitary axes(10 years)